Trial record 3 of 253 for:
Encephalitis
A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
This study has been completed.
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01092507
First received: March 23, 2010
Last updated: October 10, 2011
Last verified: October 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to compare a single dose of Japanese encephalitis (JE) chimeric virus vaccine (JE-CV) with a single dose of SA14-14-2 live vaccine as primary vaccination in infants and toddlers.
Primary Objective:
- To demonstrate the non-inferiority of the antibody response 28 days after vaccine administration of one dose of JE CV (administered on Day 0) compared to the antibody response after one dose of the SA14-14-2 control vaccine (administered on Day 0).
Secondary Objectives:
- To describe the immune response to JE in both vaccine groups in JE-CV virus and SA14-14-2 virus before and after a single dose of JE CV or a single dose of SA14-14-2 vaccine
- To describe the safety profile in all vaccinated subjects up to 28 days and all serious adverse events (SAEs) up to 6 months after vaccination.
- To describe only related SAEs and all death from 6 month to 12-month follow-up.
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis Japanese Encephalitis |
Biological: Japanese encephalitis chimeric virus vaccine (JE CV) Biological: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Controlled Study of the Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Comparison With SA14-14-2 Vaccine in Infants and Toddlers in Thailand - Primary Vaccination and Long-term Follow-up to 5 Years Post-vaccination |
Resource links provided by NLM:
Further study details as provided by Sanofi:
Primary Outcome Measures:
- Immunogenicity in terms of seroconversion post-vaccination with Japanese encephalitis chimeric virus vaccine. [ Time Frame: 28 days post-vaccination ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Safety in terms of solicited injection site and systemic events, and serious adverse events (SAEs) after primary administration of Japanese encephalitis chimeric virus vaccine. [ Time Frame: 0-14 days and up to 12 months post-vaccination ] [ Designated as safety issue: Yes ]
| Enrollment: | 300 |
| Study Start Date: | March 2010 |
| Study Completion Date: | October 2011 |
| Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: JE-CV Group
Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
|
Biological: Japanese encephalitis chimeric virus vaccine (JE CV)
0.5 mL, Subcutaneous
|
|
Active Comparator: SA14-14-2 vaccine Group
Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
|
Biological: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
0.5 mL, Subcutaneous
Other Name: CD.JEVAX®
|
Detailed Description:
All participants will receive one injection of their randomized vaccine on Day 0. Follow-up will continue for 12 months after vaccination.
Eligibility| Ages Eligible for Study: | 9 Months to 18 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria :
- Aged 9 to 18 months on the day of inclusion
- In good general health, without significant medical history
- Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations
- Subject and parent/legally acceptable representatives able to attend all scheduled visits and comply with all trial procedures
- Completion of vaccinations according to the national immunization schedule.
Exclusion Criteria :
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
- Planned participation in another clinical trial during the present trial period
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances
- Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator
- Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of the immune response
- Previous vaccination against flavivirus disease, including Japanese encephalitis (JE)
- Administration of any anti-viral within 2 months preceding first vaccination and up to the 4 weeks following the last trial vaccination at Month 3
- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination
- Planned receipt of any vaccine from the inclusion up to the 4 weeks following the last trial vaccination at Month 3
- Planned receipt of any Japanese encephalitis vaccine during the course of the study (up to Year 5)
- History of central nervous system disorder or disease, including seizures
- History of flavivirus infection (confirmed either clinically, serologically or microbiologically)
- Febrile illness (temperature ≥ 38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.
Contacts and Locations More Information
Additional Information:
No publications provided
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT01092507 History of Changes |
| Other Study ID Numbers: | JEC07, UTN: U1111-1112-2269 |
| Study First Received: | March 23, 2010 |
| Last Updated: | October 10, 2011 |
| Health Authority: | Thailand: Food and Drug Administration |
Keywords provided by Sanofi:
|
Encephalitis Japanese Encephalitis Japanese Encephalitis Vaccines Infant |
Additional relevant MeSH terms:
|
Encephalitis Encephalitis, Japanese Encephalitis, Arbovirus Encephalitis, Viral Central Nervous System Viral Diseases Virus Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Central Nervous System Infections Arbovirus Infections RNA Virus Infections Flavivirus Infections Flaviviridae Infections |
ClinicalTrials.gov processed this record on May 22, 2013